Nabumet - 500mg

Tablet

Pack Size : 10 Tablet x 1 Strip

Generics : Nabumetone

Manufacturer : Eskayef Pharmaceuticals Ltd.

Best Price * TK 150.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Elivier - 500 mg Incepta Pharmaceuticals Ltd.

Tk 15.00

Tablet Nabu - 500mg Eskayef Pharmaceuticals Ltd.

Tk 15.00

Tablet Buflex 500mg - 500 Beximco Pharmaceuticals Ltd.

Tk 15.00

More Information About - Nabumet - 500mg

Description

Generic Name

Nabumetone

Precaution

Pre-existing CV risk factors or disease; fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Elderly or debilitated patients. Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment; rehydrate patient prior to therapy and closely monitor renal function. Withhold for at least 4-6 half-lives prior to surgical or dental procedures.

Indication

Relieve of, Acute & Chronic Pain and inflammation, associated with Osteoarthritis, Rheumatoid Arthritis and Musculoskeletal & joint disorders,

Contra Indication

Absolute: Aspirin allergy, severe renal impairment; perioperative pain in setting of coronary artery bypass graft (CABG) surgery Relative: Duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus, ulcerative colitis, late pregnancy (may cause premature closure of ductus arteriosus)

Dose

N/A

Side Effect

>10% Diarrhea (14%),Dyspepsia (13%),Abdominal pain (12%) 1-10% Constipation (3-9%),Dizziness (3-9%),Edema (3-9%),Flatulence (3-9%),Headache (3-9%),Nausea (3-9%),Positive stool guaiac (3-9%),Pruritus (3-9%),Rash (3-9%),Tinnitus (3-9%),Dry mouth (1-3%),Fatigue (1-3%),Gastritis (1-3%),Increased sweating (1-3%),Insomnia (1-3%),Nervousness (1-3%),Somnolence (1-3%),Stomatitis (1-3%),Vomiting (1-3%)

Pregnancy Category

Name : C

Description

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Mode of Action

Inhibits synthesis of prostaglandins in body tissues by inhibiting at least 2 cyclooxygenase (COX) isoenzymes, COX-1 and COX-2 May inhibit chemotaxis, alter lymphocyte activity, decrease proinflammatory cytokine activity, and inhibit neutrophil aggregation; these effects may contribute to anti-inflammatory activity

Interaction

Antihypertensive effects of hypotensive agents may be reduced. May increase ciclosporin levels. Increased risk of seizures with fluoroquinolones. May reduce efficacy of diuretics. May diminish the cardioprotective effect of acetylated salicylates. Alcohol may enhance gastric mucosal irritation. Potentially Fatal: Increased risk of bleeding with anticoagulants (e.g. warfarin, heparin, LMWHs) and antiplatelet agents (e.g. ticlopidine, clopidogrel, aspirin, abciximab, dipyridamole, eptifibatide, tirofiban). Increased risk of GI ulceration with corticosteroids. Severe bone marrow suppression, aplastic anaemia and GI toxicity may occur with methotrexate.

Pregnancy Category Note

Pregnancy category: C; D if used for prolonged periods or near term (premature closure of ductus arteriosus) Lactation: Unknown whether drug is excreted in breast milk; effect on infant unknown; do not give to nursing mothers

Adult Dose

Oral Adult Osteoarthritis 1g PO once daily initially; maintenance: 1-2 g/day PO in single daily dose or divided q12hr; not to exceed 2 g/day Rheumatoid Arthritis 1 g PO once daily initially; maintenance: 1-2 g/day PO in single daily dose or divided q12hr; not to exceed 2 g/day Elderly: 500 mg daily may be adequate in certain patients. Max: 1 g daily.

Child Dose

Not recommended

Renal Dose

Renal impairment: CrCl (ml/min) Dosage Recommendation 30-49 Max initial dose: 750 mg once daily. Increase if needed to a max dose of 1.5 g daily. <30 Max initial dose: 500 mg once daily. Increase if needed to a max dose of 1 g daily.

Administration

Should taken with food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.